Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease

Executive Summary

This study included 31 allergic dogs with chronic pruritis with other skin diseases excluded.

Dogs were split into 3 treatment groups based on degree of pruritis, distribution, extension of the lesions and skin and coat condition;

Group 1: mild,

Group 2: moderate,

and Group 3: severe.

All dogs received PCSO-524 loading dose 10 mg/kg q12hr PO for 2 weeks followed by a maintenance dose of 10 mg/kg q24hr PO.

All dogs were evaluated at 2, 4, 8, 12 and 16 weeks for clinical response.

The assessment made by the owners (PVAS Score) and Vets (CADESI-03 score).

The results demonstrated that PCS0-524 had beneficial effects on improvement in skin and coat condition and a reduction in PVAS score in Group 1. Similarly, vet evaluation revealed greater reduction in pruritic score in Group 1 (50%) with less effects in Group 2 (44.44%) and Group 3 (40%).

The results of this study suggested PCSO-524 had beneficial effect in atopic skin allergy with a greater effect in mild cases.

The effect was less in more severely affected atopic dogs, probably due to  the severe degree of inflammation they experienced.

PCSO-524 may be used as treatment of canine atopic dermatitis.